Ocular Gene Transfer with Self-Complementary AAV Vectors
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
PURPOSE: Self-complementary AAV (scAAV) vectors have been developed to circumvent rate-limiting second-strand synthesis in single-stranded AAV vector genomes and to facilitate robust transgene expression at a minimal dose. In this study, the authors investigated the effects of intraocular injections of type 2 scAAV.GFP in mice. METHODS: Dose-response experiments were performed to compare conventional single-strand AAV type 2 (ssAAV2) vectors with scAAV2 vectors encoding an identical expression cassette. RESULTS: Subretinal injection of 5 x 10(8) viral particles (vp) of scAAV.CMV-GFP resulted in green fluorescent protein (GFP) expression in almost all retinal pigment epithelial (RPE) cells within the area of the small detachment caused by the injection by 3 days and strong, diffuse expression by 7 days. Expression was strong in all retinal cell layers by days 14 and 28. In contrast, 3 days after subretinal injection of 5 x 10(8) vp of ssAAV.CMV-GFP, GFP expression was detectable in few RPE cells. Moreover, the ssAAV vector required 14 days for the attainment of expression levels comparable to those observed using scAAV at day 3. Expression in photoreceptors was not detectable until day 28. Dose-response experiments confirmed that onset of GFP expression was more rapid and robust after subretinal injection of scAAV.CMV-GFP than of ssAAV.CMV-GFP, resulting in pronounced expression in photoreceptors and other retinal neurons. Similar results were obtained for intravitreous injections. CONCLUSIONS: These data suggest that scAAV vectors may be advantageous for ocular gene therapy, particularly in retinal diseases that require rapid and robust transgene expression in photoreceptor cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“When compared to ssDNA, lowered rAAV doses of scAAV gene therapy vector can be used to reach similar transgene expression levels in the retina in vivo [101,152,256,257].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [257]
Citations
Cites
Oxygen-induced retinopathy in the mouse.
Smith, L. E. H., Wesolowski, E., McLellan, A., Kostyk, S. K., D’Amato, R. J., Sullivan, R., & D'Amore, P. A. (1994) · PubMed · Cited by 1,627
Ferrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761 · cited 1×
“This can be attributed to the need for efficient synthesis of the complementary strand of the singlestranded vector genome before transgene expression.(3) Self-complementary AAV (scAAV) vectors contain a doublestranded vector genome generated by deletion of the terminal resolution site (TR) from one rAAV TR, preventin…”
BackgroundSelf-citationMcCarty, D., Monahan, P., & Samulski, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301514 · Cited by 735 · cited 2×
“These constructs generate single-stranded, inverted-repeat genomes, with a wildtype (wt) TR at each end and a mutated TR in the middle.(4) Compared with single-strand AAV (ssAAV) vectors, scAAV vectors have been shown to improve transduction efficiency in liver,(5,6) trabecular meshwork,(7) and brain cells.”
BackgroundMethodSelf-citationDifferential effect of the rd mutation on rods and cones in the mouse retina.
Carter‐Dawson, L. D., LaVail, M. M., & Sidman, R. L. (1978) · PubMed · Cited by 539
Acland, G. M., Aguirre, G. D., Bennett, J., Aleman, T. S., Cideciyan, A. V., Bennicelli, J., Dejneka, N. S., Pearce-Kelling, S. E., Maguire, A. M., Palczewski, K., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.008 · Cited by 477
Nathwani, A. C., Gray, J. T., Ng, C. Y. C., Zhou, J., Spence, Y., Waddington, S. N., Tuddenham, E. G. D., Kemball-Cook, G., McIntosh, J., Boon-Spijker, M., et al. (2006) · Blood · doi:10.1182/blood-2005-10-4035 · Cited by 421
Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus
Flannery, J. G., Zolotukhin, S., Vaquero, M. I., LaVail, M. M., Muzyczka, N., & Hauswirth, W. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6916 · Cited by 407
Okamoto, N., Tobe, T., Hackett, S. F., Ozaki, H., Vinores, M. A., La Rochelle, W., Zack, D. J., & Campochiaro, P. A. (1998) · Retina · doi:10.1097/00006982-199805000-00034 · Cited by 365
Self-citationGrimm, D., & Kay, M. (2003) · Current Gene Therapy · doi:10.2174/1566523034578285 · Cited by 350
Real-time, noninvasive in vivo assessment of adeno-associated virus-mediated retinal transduction.
Bennett, J., Duan, D., Engelhardt, J. F., & Maguire, A. M. (1997) · PubMed · Cited by 204
Cited by
Self-complementary AAV vectors; advances and applications
McCarty, D. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.171 · Cited by 515
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors
Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.-H., Chiodo, V., Pang, J.-J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A. S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.269 · Cited by 398
Vector platforms for gene therapy of inherited retinopathies
Trapani, I., Puppo, A., & Auricchio, A. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.08.001 · Cited by 183
Clinical applications of retinal gene therapy
Lipinski, D. M., Thake, M., & MacLaren, R. E. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2012.09.001 · Cited by 132
AAV-mediated gene therapy for retinal disorders: from mouse to man
Buch, P. K., Bainbridge, J. W., & Ali, R. R. (2008) · Gene Therapy · doi:10.1038/gt.2008.66 · Cited by 134
Dalkara, D., Kolstad, K. D., Guerin, K. I., Hoffmann, N., Visel, M., Klimczak, R. R., Schaffer, D. V., & Flannery, J. G. (2011) · Molecular Therapy · doi:10.1038/mt.2011.62 · Cited by 121
Buck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
“When compared to ssDNA, lowered rAAV doses of scAAV gene therapy vector can be used to reach similar transgene expression levels in the retina in vivo [101,152,256,257].”
BackgroundRahim, A. A., Wong, A. M. S., Hoefer, K., Buckley, S. M. K., Mattar, C. N., Cheng, S. H., Chan, J. K. Y., Cooper, J. D., & Waddington, S. N. (2011) · The FASEB Journal · doi:10.1096/fj.11-182311 · Cited by 97
Dosage thresholds and influence of transgene cassette in adeno-associated virus–related toxicity
Khabou, H., Cordeau, C., Pacot, L., Fisson, S., & Dalkara, D. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.144 · Cited by 93
Gene therapy for retinal disease
McClements, M. E., & MacLaren, R. E. (2013) · Translational Research · doi:10.1016/j.trsl.2012.12.007 · Cited by 80
“Compared with the standard rAAV2/2 equivalent vector, scAAV initiated more rapid onset of reporter gene expression following subretinal delivery to mouse retina in both RPE and photoreceptor cells.(62) Comparisons of transduction from scAAV2/2, scAAV2/5, and scAAV2/8 compared with rAAV2/8 found consistently faster ons…”
Pang, J., Boye, S. E., Lei, B., Boye, S. L., Everhart, D., Ryals, R., Umino, Y., Rohrer, B., Alexander, J., Li, J., et al. (2010) · Gene Therapy · doi:10.1038/gt.2010.29 · Cited by 70
Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications
Schön, C., Biel, M., & Michalakis, S. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.01.009 · Cited by 77
Corneal Gene Therapy: Basic Science and Translational Perspective
Mohan, R. R., Rodier, J. T., & Sharma, A. (2013) · The Ocular Surface · doi:10.1016/j.jtos.2012.10.004 · Cited by 63
Woodard, K. T., Liang, K. J., Bennett, W. C., & Samulski, R. J. (2016) · Journal of Virology · doi:10.1128/jvi.01568-16 · Cited by 59
Self-citationAAV for Gene Therapy in Ocular Diseases: Progress and Prospects
He, X., Fu, Y., Ma, L., Yao, Y., Ge, S., Yang, Z. H., & Fan, X. (2023) · Research · doi:10.34133/research.0291 · Cited by 79
Retinal Ganglion Cell Gene Therapy and Visual System Repair
Hellström, M., & Harvey, A. R. (2011) · Current Gene Therapy · doi:10.2174/156652311794940746 · Cited by 60
Askou, A. L., Pournaras, J. C., Pihlmann, M., Svalgaard, J. D., Arsenijevic, Y., Kostic, C., Bek, T., Dagnæs‐Hansen, F., Mikkelsen, J. G., Jensen, T. G., et al. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2678 · Cited by 55
Novel insights into gene therapy in the cornea
Mohan, R. R., Martin, L. M., & Sinha, N. R. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108361 · Cited by 56
Hellström, M., Pollett, M. A., & Harvey, A. R. (2011) · Journal of Neurotrauma · doi:10.1089/neu.2011.1928 · Cited by 55
Kong, F., Li, W., Li, X., Zheng, Q., Dai, X., Zhou, X., Boye, S. L., Hauswirth, W. W., Qu, J., & Pang, J.-J. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.01.011 · Cited by 51
Gene Therapy of Inherited Retinopathies: A Long and Successful Road from Viral Vectors to Patients
Colella, P., & Auricchio, A. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.123 · Cited by 50
Koilkonda, R. D. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.135 · Cited by 48
Li, W., Kong, F., Li, X., Dai, X., Liu, X., Zheng, Q., Wu, R., Zhou, X., Lü, F., Chang, B., et al. (2009) · PubMed · Cited by 52
Mookherjee, S., Hiriyanna, S., Kaneshiro, K., Li, L., Li, Y., Li, W., Qian, H., Li, T., Khanna, H., Colosi, P., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv354 · Cited by 51
Petersen‐Jones, S. M., Bartoe, J. T., Fischer, A. J., Scott, M. A., Boye, S. L., Chiodo, V. A., & Hauswirth, W. W. (2009) · PubMed Central · Cited by 42
De Silva, S. R., Charbel Issa, P., Singh, M. S., Lipinski, D. M., Barnea-Cramer, A. O., Walker, N. J., Barnard, A. R., Hankins, M. W., & MacLaren, R. E. (2016) · Gene Therapy · doi:10.1038/gt.2016.54 · Cited by 29
Regenerative nanomedicine and the treatment of degenerative retinal diseases
Zarbin, M. A., Montemagno, C. D., Leary, J. F., & Ritch, R. H. (2011) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.167 · Cited by 29
A drug-tunable Flt23k gene therapy for controlled intervention in retinal neovascularization
Chen, J., Lin, F., Leung, J. Y. K., Tu, L., Wang, J.-H., Chuang, Y.-F., Fan, L., Shen, H., Dusting, G. J., Wong, V. H. Y., et al. (2020) · Angiogenesis · doi:10.1007/s10456-020-09745-7 · Cited by 29
Raj, D., Davidoff, A. M., & Nathwani, A. C. (2011) · Expert Review of Hematology · doi:10.1586/ehm.11.48 · Cited by 27
Doxorubicin augments rAAV-2 transduction in rat neuronal cells
Zhang, T., Hu, J., Ding, W., & Wang, X. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.05.005 · Cited by 23
Rapid and Stable Knockdown of an Endogenous Gene in Retinal Pigment Epithelium
Paskowitz, D. M., Greenberg, K. P., Yasumura, D., Grimm, D., Yang, H., Duncan, J. L., Kay, M. A., LaVail, M. M., Flannery, J. G., & Vollrath, D. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.065 · Cited by 24
Greenwald, S. H., Brown, E. E., Scandura, M. J., Hennessey, E., Farmer, R., Pawlyk, B. S., Xiao, R., Vandenberghe, L. H., & Pierce, E. A. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.07.003 · Cited by 23
Gruenert, A. K., Czugala, M., Mueller, C., Schmeer, M., Schleef, M., Kruse, F. E., & Fuchsluger, T. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152589 · Cited by 21
Zeng, R., Zhang, Y., Shi, F., & Kong, F. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-8241 · Cited by 18
Just a SNP away: The future of in vivo massively parallel reporter assay
Degner, K. N., Bell, J., Jones, S. D., & Won, H. (2024) · Cell Insight · doi:10.1016/j.cellin.2024.100214 · Cited by 16
Transfer of gene to human retinal pigment epithelial cells using magnetite cationic liposomes
Fujii, Y., Kachi, S., Itô, A., Kawasumi, T., Honda, H., & Terasaki, H. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2009.161109 · Cited by 14
Self-citationChallenges in AAV-Based Retinal Gene Therapies and the Role of Magnetic Nanoparticle Platforms
Siontas, O., & Ahn, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237385 · Cited by 13
Adeno-Associated Viral Gene Therapy for Retinal Disorders
Silva, S. R. D., McClements, M. E., Hankins, M. W., & MacLaren, R. E. (2015) · Neuromethods · doi:10.1007/978-1-4939-2306-9_9 · Cited by 11
Identification of Key Residues Determining Isomerohydrolase Activity of Human RPE65
Takahashi, Y., Moiseyev, G. P., & Ma, J.-X. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.558619 · Cited by 10
Retinal transduction profiling of diverse AAV serotypes via intravitreal injection
Zhang, T., Wang, F., Wu, Y., Cao, J., & Shen, Y. (2025) · Journal of Virology · doi:10.1128/jvi.00637-25 · Cited by 10
Viral vectors for targeting the canine retina: a review
Petersen‐Jones, S. M. (2012) · Veterinary Ophthalmology · doi:10.1111/j.1463-5224.2012.01054.x · Cited by 8
Zarbin, M. A., Leary, J. F., Montemagno, C. D., Ritch, R. H., & Humayun, M. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00036-9 · Cited by 7
Jiang, W., Gong, M., Shen, L., Yu, C., Ruan, H., Chen, P., Gao, S.-H., & Xiao, Z. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04713-y · Cited by 5
Bee, Y., Tu, L., Sheu, S., Lin, H.-C., Tang, J.-H., Wang, J.-H., Prea, S. M., Dusting, G. J., Wu, D., Zhong, J., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.035 · Cited by 5
Dong, F., Amlal, H., Venkatakrishnan, J., Zhang, J., Fry, M. V., Yuan, Y., Cheng, Y. C., Hu, Y., & Kao, W. W. ‐. (2023) · The Ocular Surface · doi:10.1016/j.jtos.2023.06.002 · Cited by 2
Venkatakrishnan, J., Yuan, Y., Zhang, J., Yu, Y., Hu, Y., & Kao, W. W. ‐. (2024) · The Ocular Surface · doi:10.1016/j.jtos.2024.01.002 · Cited by 2
Ryabova, E. I., Derkaev, A. A., Esmagambetov, I. B., Dovgiy, M. A., Blinov, A. A., Hossain, R. M., Dmitriev, O. E., Polyansky, D. S., Noskov, A. N., Shcheblyakov, D. V., et al. (2026) · Fine Chemical Technologies · doi:10.32362/2410-6593-2025-20-6-582-593 · Cited by 1
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_150-1 · Cited by 1
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_150 · Cited by 1
Viral vector-mediated RNA interference in the retina
Georgiadis, A. (2010) · UCL Discovery (University College London)
Rudanko, S. (2007) · Helda - University of Helsinki Institutional Repository · Cited by 1
Maina, C. N. (2009) · IUScholarWorks (Indiana University) · doi:10.7912/c2/1689
Gene Therapy for Retinal Disease
McClements, M. E., & MacLaren, R. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00011-7 · Cited by 1
Rescue of inherited retinal degeneration associated with Aipl1 defects
Ku, C. A. (2012) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.4880
Rapid TetOn-mediated gene expression in neurons across the lifespan with uTTOPPreprint
Salmon, C. K., Quesseveur, G., Cheong, G. H. L., Chierzi, S., Green, M., Rosen, M. P., Gao, A. Y. L., Kacerovsky, J. B., & Murai, K. K. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.05.570307
Pathophysiology and gene therapy of the optic neuropathy in Wolfram Syndrome
Jagodzinska, J. (2016) · theses.fr (ABES) · doi:10.70675/d5ad003czb010z456bz8738za3feee533351
Dillinger, A. E., Jaegle, H., Fuchs, H., Strobel, B., Redemann, N. H., & Tamm, E. R. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201795 · Cited by 1
Ocular Gene Therapy in China: Technological Framework, Clinical Translation, and Future Perspectives
Zhang, D., He, Z., Lu, F., & Yang, Y. (2026) · Human Gene Therapy · doi:10.1177/10430342261495300
Metadata
- Authors
- Yokoi, K., Kachi, S., Zhang, H. S., Gregory, P. D., Spratt, S. K., Samulski, R. J., & Campochiaro, P. A.
- Affiliations
- Johns Hopkins University (US)
- Sangamo BioSciences (United States) (US)
- University of North Carolina at Chapel Hill (US)
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2007-07-01
- Volume
- 48
- Issue
- 7
- Pages
- 3324
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2026081637
- Cited by
- 58
- References
- 15
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 1 · 2021: 1 · 2020: 4 · 2018: 1 · 2017: 1 · 2016: 4 · 2015: 4 · 2014: 2 · 2013: 2 · 2012: 7
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- self-complementary AAV vectors, ocular gene therapy, subretinal injection, intravitreal injection, AAV2, second-strand synthesis, retinal pigment epithelium, dose-response relationship, GFP expression, retinal disease
- MeSH terms
- Dependovirus, Animals, Female, Gene Expression Regulation, Genetic Vectors, Mice, Inbred BALB C, Microscopy, Fluorescence, Pigment Epithelium of Eye, Plasmids, Genetic Therapy, Gene Transfer Techniques, Transgenes, Green Fluorescent Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.